Black Diamond Therapeutics (BDTX) Total Liabilities (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Total Liabilities came in at $28.6 million in Q1 2026, down 17.58% YoY from $34.7 million in Q1 2025, and down 7.07% on a QoQ basis from $30.8 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Total Liabilities (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Total Liabilities data on file, last reported at $28.6 million in Q1 2026.
- Quarterly Total Liabilities fell 17.58% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (down 17.58% YoY) and the FY2025 annual result came in at $30.8 million, down 21.74% from the prior year.
- Total Liabilities retreated to $28.6 million in Q1 2026, from $30.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $47.2 million in Q3 2022 to a low of $28.6 million in Q1 2026.
- A 5-year average of $38.4 million and a median of $38.2 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 44.35% — and 2025, when it retreated 21.96%.
- Tracing BDTX's Total Liabilities over 5 years: stood at $40.6 million in 2022, then gained by 3.13% to $41.8 million in 2023, then dropped by 5.92% to $39.4 million in 2024, then fell by 21.74% to $30.8 million in 2025, then retreated by 7.07% to $28.6 million in 2026.
- The last three Total Liabilities figures came in at $28.6 million (Q1 2026), $30.8 million (Q4 2025), and $31.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 28.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.94 Mn |
| Mar 31, 2026 | 28.62 Mn |
| Dec 31, 2025 | 30.80 Mn |
| Sep 30, 2025 | 31.58 Mn |
| Jun 30, 2025 | 33.78 Mn |
| Mar 31, 2025 | 34.73 Mn |
| Dec 31, 2024 | 39.36 Mn |
| Sep 30, 2024 | 40.47 Mn |
| Jun 30, 2024 | 38.97 Mn |
| Mar 31, 2024 | 38.22 Mn |
| Dec 31, 2023 | 41.83 Mn |
| Sep 30, 2023 | 38.07 Mn |
| Jun 30, 2023 | 37.68 Mn |
| Mar 31, 2023 | 37.39 Mn |
| Dec 31, 2022 | 40.56 Mn |
| Sep 30, 2022 | 47.19 Mn |
| Jun 30, 2022 | 46.46 Mn |
| Mar 31, 2022 | 46.92 Mn |
| Dec 31, 2021 | 51.78 Mn |
| Sep 30, 2021 | 55.18 Mn |